Who
Stephen Ray Mitchell
Director
Company insider
Files Form 4 as: Director, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $540K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 14 Feb 2020
- Last trade
- 4 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 8 Jun 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —41,600 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —41,600 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —25,836 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code G | —25,836 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $32K7,000 at $4.59 | filing |
| 5 Jun 2025filed 9 Jun 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —59,225 at $0.00 | filing |
| 14 Nov 2024filed 18 Nov 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $26K5,000 at $5.17 | filing |
| 17 May 2024filed 21 May 2024 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —37,578 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —20,529 at $0.00 | filing |
| 10 Aug 2023filed 11 Aug 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $39K6,500 at $6.05 | filing |
| 8 Jun 2023filed 12 Jun 2023 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —33,960 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —17,307 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —24,707 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —12,006 at $0.00 | filing |
| 13 Jun 2022filed 14 Jun 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $26K2,700 at $9.48 | filing |
| 9 Sep 2021filed 13 Sep 2021 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,985 at $0.00 | filing |
| 9 Sep 2021filed 13 Sep 2021 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,124 at $0.00 | filing |
| 9 Sep 2021filed 13 Sep 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $63K5,985 at $10.57 | filing |
| 9 Sep 2021filed 13 Sep 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $167K13,124 at $12.70 | filing |
| 9 Sep 2021filed 13 Sep 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $320K19,109 at $16.74 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Stephen Ray Mitchell; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.